Covidien has unveiled its Emprint ablation system with Thermosphere technology, designed to precisely heat and destroy diseased soft tissue (including liver, lung and kidney), and non-resectable liver tumors.
With the Emprint ablation system, clinicians can have three kinds of spatial energy control, including thermal, field and wavelength, for creating predictable and spherical ablation zones regardless of target location, tissue type, or changes in tissue properties during a procedure.
According to Covidien, the advanced ablation system can be used in three different procedure settings, including non-surgical procedures directly through the skin, minimally invasive surgery and open surgery.
Covidien Early Technologies president Chuck Brynelsen said the company is dedicated to improving patient safety and simplifying procedural options, and this innovative technology enables physicians to deliver precise ablation directly to soft tissue, including liver tumors.
"By providing predictable spherical ablation zones, this technology gives physicians more choices in terms of approach, further simplifying needle placement and saving planning and procedure time," Brynelsen added.
Covidien had obtained 510(k) clearance from the US Food and Drug Administration for the Emprint ablation system with Thermosphere Technology in April 2014. The company has also completed all European requirements to CE Mark the product.
The Emprint system is expected to be fully launched in the US and EU during the current quarter.
Image: Covidien’s Emprint ablation system with Thermosphere technology. Photo: Courtesy of Business Wire